Silkworm ‘micrococoons’ could be used in biotechnology and medicine
- Micrococoons like those spun by silkworms have been created by University of Sheffield and Cambridge researchers.
- The tiny capsules could help protect sensitive molecules that have potential health or nutritional benefits.
- The technology could also be used in pharmaceuticals to treat a wide range of severe and debilitating illnesses.
Researchers at the University of Sheffield have helped to manufacture microscopic versions of the cocoons spun by silkworms, in order to store sensitive proteins – technology which could be used in pharmaceuticals to treat a range of debilitating illnesses.
The tiny capsules, which are invisible to the naked eye, can protect sensitive molecular materials and could prove a significant technology in areas including food science, biotechnology and medicine.
The capsules were made by researchers from at the University of Cambridge with help from engineers from the University of Sheffield, using a specially-developed microengineering process that combines the power of microfluidic manufacturing with the value of natural silk.
The process mimics on the microscale the way in which Bombyx mori silkworms spin the cocoons from which natural silk is harvested. The resulting micron-scale capsules comprise a solid and tough shell of silk nano-fibrils that surround and protect a centre of liquid cargo, and are more than a thousand times smaller than those created by silkworms.
Writing in the journal Nature Communications, the team suggests that these ‘micrococoons’ are a potential solution to a common technological problem: how to protect sensitive molecules that have potential health or nutritional benefits, but can easily degrade and lose these favourable qualities during storage or processing.
The study argues that sealing such molecules in a protective layer of silk could be the answer, and that silk micrococoons that are far too small to see (or taste) could be used to house tiny particles of beneficial molecular “cargo” in various products, such as cosmetics and food.
The same technology could also be used in pharmaceuticals to treat a wide range of severe and debilitating illnesses. In the study, the researchers successfully showed that silk micrococoons can increase the stability and lifetime of an antibody that acts on a protein implicated in neurodegenerative diseases.
The work was carried out by an international team of academics from the Universities of Cambridge, Sheffield and Oxford in the UK; the Swiss Federal Institute of Technology in Zurich, Switzerland; and the Weizmann Institute of Science in Israel.
The study was led by Professor Tuomas Knowles, a Fellow of St John’s College at the University of Cambridge and co-director of the Centre for Protein Misfolding Diseases.
“It is a common problem in a range of areas of great practical importance to have active molecules that possess beneficial properties but are challenging to stabilise for storage,” said Professor Knowles.
“A conceptually simple, but powerful, solution is to put these inside tiny capsules. Such capsules are typically made from synthetic polymers, which can have a number of drawbacks, and we have recently been exploring the use of fully natural materials for this purpose.
“We are particularly excited by the potential to replace plastics with sustainable biological materials for this purpose.”
Dr Chris Holland, co-worker and head of the Natural Materials Group from the University of Sheffield’s Department of Materials Science and Engineering, added: “Silk is amazing because whilst it is stored as a liquid, spinning transforms it into a solid. This is achieved by stretching the silk proteins as they flow down a microscopic tube inside the silkworm.”
To imitate this, the researchers created a tiny, artificial spinning duct, which copies the natural spinning process to cause the unspun silk to form into a solid. The researchers then worked out how to control the geometry of this self-assembly in order to create microscopic shells.
Making conventional synthetic capsules can be challenging to achieve in an environmentally friendly manner and from biodegradable and biocompatible materials. Silk is not only easier to produce; it is also biodegradable and requires less energy to manufacture.
“Natural silk is already being used in products like surgical materials, so we know that it is safe for human use,” Professor Fritz Vollrath head of the Oxford Silk Group said.
“Importantly, the approach does not change the material, just its shape.”
Silk micrococoons could also expand the range and shelf-life of proteins and molecules available for pharmaceutical use. Because the technology can preserve antibodies, which would otherwise degrade, in cocoons with walls that can be designed to dissolve over time, it could enable the development of new treatments against cancer, or neurodegenerative conditions such as Alzheimer’s and Parkinson’s Diseases.
To explore the viability of silk microcapsules in this regard, the researchers successfully tested the micrococoons with an antibody that has been developed to act on alpha-synuclein, the protein that is thought to malfunction at the start of the molecular process leading to Parkinson’s Disease. This study was carried out with the support of the Cambridge Centre for Misfolding Diseases, whose research programme is focused on the search for ways of preventing and treating neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.
The study, Silk microcooons for protein stabilisation and molecular encapsulation, is published in Nature Communications.
For the full study please visit: https://www.nature.com/articles/ncomms15902
The University of Sheffield
With almost 27,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2017 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014. In the last decade it has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For further information, please visit www.sheffield.ac.uk
For further information please contact:
Media Relations Officer
University of Sheffield
0114 222 9859